User login
Integrating Advances in Insulin into Clinical Practice
The goal of this 32-page supplement is to provide insight into the continuing evolution of insulin and to provide solutions to the challenges faced in managing patients taking insulin in the primary care setting. Topics covered include “Overview of Current Insulin Formulations,” by Andrew S. Rhinehart, MD; “Advances in Insulin Formulations,” by Allen King, MD; and “Effective Utilization of Insulin in Patient Management,” by Michael K. Heile, MD and Timothy S. Reid, MD.
The goal of this 32-page supplement is to provide insight into the continuing evolution of insulin and to provide solutions to the challenges faced in managing patients taking insulin in the primary care setting. Topics covered include “Overview of Current Insulin Formulations,” by Andrew S. Rhinehart, MD; “Advances in Insulin Formulations,” by Allen King, MD; and “Effective Utilization of Insulin in Patient Management,” by Michael K. Heile, MD and Timothy S. Reid, MD.
The goal of this 32-page supplement is to provide insight into the continuing evolution of insulin and to provide solutions to the challenges faced in managing patients taking insulin in the primary care setting. Topics covered include “Overview of Current Insulin Formulations,” by Andrew S. Rhinehart, MD; “Advances in Insulin Formulations,” by Allen King, MD; and “Effective Utilization of Insulin in Patient Management,” by Michael K. Heile, MD and Timothy S. Reid, MD.
Chronic Pain Perspectives—September 2013
• How best to prevent acute pain from becoming chronic
• One practice's success with platelet-rich plasma therapy
• Neurogenic thoracic outlet syndrome: An often overlooked but treatable condition
• Obesity-related pain: Time for a new approach that targets systemic inflammation
• How best to prevent acute pain from becoming chronic
• One practice's success with platelet-rich plasma therapy
• Neurogenic thoracic outlet syndrome: An often overlooked but treatable condition
• Obesity-related pain: Time for a new approach that targets systemic inflammation
• How best to prevent acute pain from becoming chronic
• One practice's success with platelet-rich plasma therapy
• Neurogenic thoracic outlet syndrome: An often overlooked but treatable condition
• Obesity-related pain: Time for a new approach that targets systemic inflammation
Neurogenic thoracic outlet syndrome: An often overlooked but treatable condition
One practice’s success with platelet-rich plasma therapy
How best to prevent acute pain from becoming chronic?
JOURNAL SCANSummary of Key ArticlesExploring the Role of Metanx® in Diabetic Neuropathy
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
A supplement to Internal Medicine News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
A supplement to Internal Medicine News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
A supplement to Internal Medicine News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
JOURNAL SCAN Summary of Key ArticlesExploring the Role of Metanx® in Diabetic Neuropathy
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
A supplement to Family Practice News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
A supplement to Family Practice News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
A supplement to Family Practice News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
JOURNAL SCANSummary of Key ArticlesExploring the Role of Metanx® in Diabetic Neuropathy
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
A supplement to Clinical Endocrinology News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
A supplement to Clinical Endocrinology News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
A supplement to Clinical Endocrinology News. This supplement was sponsored by Nestlé Health Science-Pamlab, Inc.
Topics
- Introduction
- Prevalence and Etiology
- Signs and Symptoms
- Disease Progression
- Shortcomings of Available Palliative Prescription Therapies
- Role of Metanx® in Diabetic Neuropathy
- A Randomized Trial of Metanx® in Patients with Type 2 Diabetes and Peripheral Neuropathy
- Efficacy of Metanx® in Treating Peripheral Neuropathy and Increasing Nerve Fiber Density in Zucker Diabetic Fatty Rats
Faculty/Faculty Disclosures
Aaron I. Vinik, MD, PhD
Professor of Medicine/Pathology/Neurobiology
Director of Research and Neuroendocrine Unit
Murray Waitzer Endowed Chair of Diabetes Research
Strelitz Diabetes Center for Endocrine and Metabolic Disorders
Eastern Virginia Medical School
Norfolk, Virginia
Dr Vinik has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
Dr Fonseca reports that he has served as a consultant for Nestlé Health Science-Pamlab, Inc., and has received compensation from Nestlé Health Science-Pamlab, Inc., for his participation in preparing this supplement.
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
Summary of Key Articles
Exploring the Role of Metanx® in Diabetic Neuropathy
Knowing your patients’ cancer family history saves lives
With genomic technology advancing rapidly, we are quickly progressing into an exciting era where we will be able to practice truly personalized medicine and tailor patient care based on individual risk. To illustrate, every woman fits into one of 3 risk categories for breast cancer: those that carry sporadic, familial, or hereditary cancer risk. As the de facto primary care providers for many women, we have the responsibility to stratify every patient into one of these 3 categories in order to properly adapt screening and management decisions. Additionally, a focus on family history and risk stratification allows us the opportunity to detect those patients who carry one of several genetic mutations that dramatically increase their risk of developing cancer.
With genomic technology advancing rapidly, we are quickly progressing into an exciting era where we will be able to practice truly personalized medicine and tailor patient care based on individual risk. To illustrate, every woman fits into one of 3 risk categories for breast cancer: those that carry sporadic, familial, or hereditary cancer risk. As the de facto primary care providers for many women, we have the responsibility to stratify every patient into one of these 3 categories in order to properly adapt screening and management decisions. Additionally, a focus on family history and risk stratification allows us the opportunity to detect those patients who carry one of several genetic mutations that dramatically increase their risk of developing cancer.
With genomic technology advancing rapidly, we are quickly progressing into an exciting era where we will be able to practice truly personalized medicine and tailor patient care based on individual risk. To illustrate, every woman fits into one of 3 risk categories for breast cancer: those that carry sporadic, familial, or hereditary cancer risk. As the de facto primary care providers for many women, we have the responsibility to stratify every patient into one of these 3 categories in order to properly adapt screening and management decisions. Additionally, a focus on family history and risk stratification allows us the opportunity to detect those patients who carry one of several genetic mutations that dramatically increase their risk of developing cancer.
Best Practices in IVF Nursing: Fertility preservation: Technological advances make future children possible for women undergoing cancer treatment today
The American Cancer Society estimates that, in the United States, 1,660,290 people will be diagnosed with cancer during 2013.1 About 8.9% of them, or nearly 148,000 people, will be under the age of 45, according to incidence data from the National Cancer Institute.2 We are familiar with the complex constellation of emotions – arguably even more profound when the patient is in the prime of his or her life – that surround a cancer diagnosis. Fortunately, significant advances in early diagnosis and in the efficacy of cancer therapies have led to improved long-term survival for many of these patients.
In the past, the sole focus was on preserving and prolonging life. Today, the need to address fertility concerns and other quality of life issues is recognized from the start.
The American Cancer Society estimates that, in the United States, 1,660,290 people will be diagnosed with cancer during 2013.1 About 8.9% of them, or nearly 148,000 people, will be under the age of 45, according to incidence data from the National Cancer Institute.2 We are familiar with the complex constellation of emotions – arguably even more profound when the patient is in the prime of his or her life – that surround a cancer diagnosis. Fortunately, significant advances in early diagnosis and in the efficacy of cancer therapies have led to improved long-term survival for many of these patients.
In the past, the sole focus was on preserving and prolonging life. Today, the need to address fertility concerns and other quality of life issues is recognized from the start.
The American Cancer Society estimates that, in the United States, 1,660,290 people will be diagnosed with cancer during 2013.1 About 8.9% of them, or nearly 148,000 people, will be under the age of 45, according to incidence data from the National Cancer Institute.2 We are familiar with the complex constellation of emotions – arguably even more profound when the patient is in the prime of his or her life – that surround a cancer diagnosis. Fortunately, significant advances in early diagnosis and in the efficacy of cancer therapies have led to improved long-term survival for many of these patients.
In the past, the sole focus was on preserving and prolonging life. Today, the need to address fertility concerns and other quality of life issues is recognized from the start.